Streetbeat News

NAMS

NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com

Industry

Biotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Open

22.93

Mkt cap

2.2B

Volume

596K

High

24.33

P/E Ratio

-10.91

52-wk high

26.35

Low

22.51

Div yield

N/A

52-wk low

8.64

NewAmsterdam Pharma announced positive Phase 3 BROOKLYN trial results for Obicetrapib, showing significant reductions in LDL-C levels at both Day 84 and Day 365. The drug was well-tolerated with safety comparable to placebo. A conference call is scheduled for 8:30 AM ET today.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:04 pm

NewAmsterdam Pharma (NASDAQ:NAMS) will report topline data from its Phase 3 BROOKLYN clinical trial evaluating Obicetrapib in patients with heterozygous familial hypercholesterolemia on July 29, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:02 pm

NewAmsterdam Pharma (NASDAQ:NAMS) has announced the issuance of a new patent for obicetrapib by the USPTO, extending the patent term until July 2043. This development is significant for the company's portfolio of non-statin medicines targeting cardiovascular disease.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:21 pm

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a $31 price target.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:39 pm

NewAmsterdam Pharma (NASDAQ:NAMS) will present new clinical and preclinical data on obicetrapib's impact on cardiovascular disease risk factors at upcoming medical meetings. The company is on track to report topline data from Phase 3 trials in 2024.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 12:25 pm

TD Cowen analyst Tyler Van Buren has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:12 pm

NewAmsterdam Pharma reported a Q1 EPS of $(1.06), widening from $(0.51) YoY. Cash increased to $481.1M, driven by a follow-on offering and warrant exercises. Revenue fell to $1.4M from $8.6M, with no clinical milestones achieved. R&D expenses rose to $42.4M, and SG&A expenses increased to $14.5M, reflecting growth and preparation for obicetrapib's potential launch. The net loss deepened to $93.8M from $42.0M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 1:04 pm

In Monday's after-market session, several health care stocks showed notable movements. GeneDx Holdings led the gainers with a 21.8% increase following their Q1 earnings release, while GlucoTrack experienced the largest decline among the losers, dropping 10.7%. Other notable movers included InnovAge Holding, Mustang Bio, and Vaxxinity, each responding to market dynamics and company-specific news.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 8:31 pm

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:40 am

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 9:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.